Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Methodology
2.2. Statistical Analysis
3. Results
3.1. Description of the Study Group
3.2. Vaccination Status
3.3. Approach toward Bivalent Vaccination
4. Discussion
5. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 16 August 2022).
- Norhayati, M.N.; Che Yusof, R.; Azman, Y.M. Systematic Review and Meta-Analysis of COVID-19 Vaccination Acceptance. Front. Med. 2022, 8, 3091. [Google Scholar] [CrossRef] [PubMed]
- Cascini, F.; Pantovic, A.; Al-Ajlouni, Y.A.; Failla, G.; Puleo, V.; Melnyk, A.; Lontano, A.; Ricciardi, W. Social Media and Attitudes towards a COVID-19 Vaccination: A Systematic Review of the Literature. eClinicalMedicine 2022, 48, 101454. [Google Scholar] [CrossRef] [PubMed]
- Coronavirus (COVID-19) Vaccinations—Our World in Data. Available online: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL (accessed on 15 August 2022).
- Babicki, M.; Mastalerz-Migas, A. Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. Vaccines 2022, 10, 68. [Google Scholar] [CrossRef] [PubMed]
- Spicer, K.B.; Glick, C.; Cavanaugh, A.M.; Thoroughman, D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)—Kentucky, USA, 2020. Int. J. Infect. Dis. 2022, 114, 21–28. [Google Scholar] [CrossRef]
- Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. N. Engl. J. Med. 2021, 385, e84. [Google Scholar] [CrossRef]
- Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021, 385, e83. [Google Scholar] [CrossRef]
- Menni, C.; May, A.; Polidori, L.; Louca, P.; Wolf, J.; Capdevila, J.; Hu, C.; Ourselin, S.; Steves, C.J.; Valdes, A.M.; et al. COVID-19 Vaccine Waning and Effectiveness and Side-Effects of Boosters: A Prospective Community Study from the ZOE COVID Study. Lancet Infect. Dis. 2022, 22, 1002–1010. [Google Scholar] [CrossRef]
- Rahman, S.; Rahman, M.M.; Miah, M.; Begum, M.N.; Sarmin, M.; Mahfuz, M.; Hossain, M.E.; Rahman, M.Z.; Chisti, M.J.; Ahmed, T.; et al. COVID-19 Reinfections among Naturally Infected and Vaccinated Individuals. Sci. Rep. 2022, 12, 1438. [Google Scholar] [CrossRef]
- Benotmane, I.; Gautier, G.; Perrin, P.; Olagne, J.; Cognard, N.; Fafi-Kremer, S.; Caillard, S. Antibody Response After a Third Dose of the MRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA 2021, 326, 1063–1065. [Google Scholar] [CrossRef]
- Tartof, S.Y.; Slezak, J.M.; Puzniak, L.; Hong, V.; Xie, F.; Ackerson, B.K.; Valluri, S.R.; Jodar, L.; McLaughlin, J.M. Durability of BNT162b2 Vaccine against Hospital and Emergency Department Admissions Due to the Omicron and Delta Variants in a Large Health System in the USA: A Test-Negative Case–Control Study. Lancet Respir. Med. 2022, 10, 689–699. [Google Scholar] [CrossRef]
- Willett, B.J.; Grove, J.; MacLean, O.A.; Wilkie, C.; Lorenzo, G.; Furnon, W.; Cantoni, D.; Scott, S.; Logan, N.; Ashraf, S.; et al. SARS-CoV-2 Omicron Is an Immune Escape Variant with an Altered Cell Entry Pathway. Nat. Microbiol. 2022, 7, 1161–1179. [Google Scholar] [CrossRef] [PubMed]
- Grewal, R.; Kitchen, S.A.; Nguyen, L.; Buchan, S.A.; Wilson, S.E.; Costa, A.P.; Kwong, J.C. Effectiveness of a Fourth Dose of COVID-19 MRNA Vaccine against the Omicron Variant among Long Term Care Residents in Ontario, Canada: Test Negative Design Study. BMJ 2022, 378, e071502. [Google Scholar] [CrossRef] [PubMed]
- Stokel-Walker, C. How Are Vaccines Being Adapted to Meet the Changing Face of SARS-CoV-2? BMJ 2022, 377, o1257. [Google Scholar] [CrossRef] [PubMed]
- Moderna And the European Commission (EC) Amend COVID-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 Million Doses. Available online: https://investors.modernatx.com/news/news-details/2022/Moderna-And-the-European-Commission-EC-Amend-Covid-19-Vaccine-Agreement-to-Supply-Omicron-Containing-Bivalent-Candidates-EC-Purchases-Additional-15-million-Doses/default.aspx (accessed on 16 August 2022).
- Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response against Omicron|Pfizer. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19 (accessed on 16 August 2022).
- First Bivalent COVID-19 Booster Vaccine Approved by UK Medicines Regulator. Available online: https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator (accessed on 16 August 2022).
- MZ: Czwarta Dawka Szczepionki Na COVID Przeciwko Omikronowi Nie Dla Wszystkich—Rp.Pl. Available online: https://www.rp.pl/zdrowie/art36691351-mz-czwarta-dawka-szczepionki-przeciwko-omikronowi-nie-dla-wszystkich (accessed on 16 August 2022).
- Komunikat Nr 26 Ministra Zdrowia w Sprawie Podawania Dawek Przypominających Przeciw COVID-19 w Narodowym Programie Szczepień—Ministerstwo Zdrowia—Portal Gov.Pl. Available online: https://www.gov.pl/web/zdrowie/komunikat-nr-26-ministra-zdrowia-w-sprawie-podawania-dawek-przypominajacych-przeciw-covid-19-w-narodowym-programie-szczepien (accessed on 15 August 2022).
- Johnson, A.G.; Amin, A.B.; Ali, A.R.; Hoots, B.; Cadwell, B.L.; Arora, S.; Avoundjian, T.; Awofeso, A.O.; Barnes, J.; Bayoumi, N.S.; et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence—25 U.S. Jurisdictions, 4 April–25 December 2021. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 132–138. [Google Scholar] [CrossRef] [PubMed]
- Ward, I.L.; Bermingham, C.; Ayoubkhani, D.; Gethings, O.J.; Pouwels, K.B.; Yates, T.; Khunti, K.; Hippisley-Cox, J.; Banerjee, A.; Walker, A.S.; et al. Risk of Covid-19 Related Deaths for SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta (B.1.617.2): Retrospective Cohort Study. BMJ 2022, 378, e070695. [Google Scholar] [CrossRef]
- CDC COVID Data Tracker: COVID-NET Hospitalizations by Vaccination Status. Available online: https://covid.cdc.gov/covid-data-tracker/?fbclid=IwAR2K8R4GmMfAfqRDrlOFw8NLNFrLzJxWhHvkV5VSFQ0RphUvFDok2j9cSIs#covidnet-hospitalizations-vaccination (accessed on 19 August 2022).
- Larrauri, B.J.; Malbrán, A.; Larrauri, J.A.; Larrauri, B. Omicron and Vaccines: An Analysis on the Decline in COVID-19 Mortality. medRxiv 2022. [Google Scholar] [CrossRef]
- Andrews, N.; Stowe, J.; Kirsebom, F.; Toffa, S.; Rickeard, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; O’Connell, A.-M.; et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022, 386, 1532–1546. [Google Scholar] [CrossRef]
- Kislaya, I.; Casaca, P.; Borges, V.; Sousa, C.; Ferreira, B.I.; Fonte, A.; Fernandes, E.; Matias Dias, C.; Duarte, S.; Almeida, J.P.; et al. Comparative COVID-19 Vaccines Effectiveness in Preventing Infections, Hospitalizations, and Deaths with SARS-CoV-2 BA.5 and Ba.2 Omicron Lineages: A Case-Case and Cohort Study Using Electronic Health Records in Portugal. SSRN Electron. J. 2022. [Google Scholar] [CrossRef]
- Babicki, M.; Malchrzak, W.; Mastalerz-Migas, A. Assessment of Attitudes, Main Concerns and Sources of Knowledge Regarding COVID-19 Vaccination in Poland in the Unvaccinated Individuals—A Nationwide Survey. Vaccines 2022, 10, 381. [Google Scholar] [CrossRef]
- Mylan, S.; Hardman, C. COVID-19, Cults, and the Anti-Vax Movement. Lancet 2021, 397, 1181. [Google Scholar] [CrossRef]
- Lai, C.C.; Chen, I.T.; Chao, C.M.; Lee, P.I.; Ko, W.C.; Hsueh, P.R. COVID-19 Vaccines: Concerns beyond Protective Efficacy and Safety. Expert Rev. Vaccines 2021, 20, 1013–1025. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Cheng, L.; Tao, J.; Chen, D.; Zeng, C. Knowledge and Willingness to Receive a COVID-19 Vaccine: A Survey from Anhui Province, China. Hum. Vaccin. Immunother. 2022, 18, 2024064. [Google Scholar] [CrossRef] [PubMed]
- Fang, Z.; Chen, S. Bivalent MRNA Vaccine Booster Induces Robust Antibody Immunity against Omicron Subvariants BA.2, BA.2.12.1 and BA.5. bioRxiv 2022. [Google Scholar] [CrossRef]
- Summary of Product Characteristics. Available online: https://www.medicines.org.uk/emc/product/13983/smpc#gref (accessed on 19 August 2022).
Variable | N (%) | |
---|---|---|
Age M± SD | 36.6 ± 9.67 | |
Sex | Male | 117 (20.7) |
Female | 447 (79.3) | |
Place of residence | Rural area | 80 (14.2) |
City of up to 50,000 inhabitants | 99 (17.5) | |
City of 50,000–250,000 inhabitants | 133 (23.6) | |
City with more than 250,000 inhabitants | 252 (44.7) | |
Education | Higher | 487 (86.3) |
Secondary | 77 (13.7) | |
Other | 0 (0.0) | |
Relationship status | Single | 110 (19.5) |
Partnership | 103 (18.3) | |
Married | 351 (62.2) | |
Healthcare professional | Yes | 199 (35.3) |
No | 365 (64.7) | |
Chronic conditions | Yes | 254 (45.0) |
No | 310 (55.0) |
Variable | N (%) | |
---|---|---|
Vaccination against COVID-19 | Booster dose | 390 (69.1) |
Basic vaccination scheme | 95 (16.8) | |
Incomplete scheme | 0 (0.0) | |
Unvaccinated | 79 (14.1) | |
COVID-19 vaccines taken (n = 485) | Pfizer/BioNTech | 311 (64.1) |
Moderna | 39 (8.1) | |
AstraZeneca | 33 (6.8) | |
Johnson&Johnson | 18 (3.7) | |
Mixed | 84 (17.3) | |
Adverse events following COVID-19 vaccination (n = 485) | Severe | 0 (0.0) |
Moderate | 69 (14.2) | |
Mild | 276 (56.9) | |
None | 140 (28.9) | |
Vaccination history | Mandatory and recommended | 295 (52.3) |
Only mandatory | 231 (41.0) | |
No | 38 (6.7) | |
Willingness to take the booster dose | Yes, as soon as possible | 299 (53.0) |
Yes, within a year | 69 (12.2) | |
Yes, but in a year or more | 8 (1.4) | |
I cannot decide | 46 (8.2) | |
No, but maybe in the future | 43 (7.6) | |
No, never | 99 (17.6) |
Variable | Influence on Vaccination Decision N (%) | Preferred Vaccination N (%) | |||||||
---|---|---|---|---|---|---|---|---|---|
Acceleration | Deferral | Does Not Matter | p | Bivalent | Monovalent | Does Not Matter | p | ||
Sex | Male | 33 (28.2) | 12 (10.3) | 72 (64.2) | <0.001 | 67 (57.3) | 15 (12.8) | 35 (29.9) | <0.001 |
Female | 157 (35.1) | 3 (0.7) | 287 (64.2) | 341 (76.3) | 7 (1.6) | 99 (22.1) | |||
Place of residence | Rural area | 29 (36.3) | 4 (5.0) | 47 (58.7) | 0.691 | 54 (67.5) | 4 (5.0) | 22 (27.5) | <0.001 |
City of up to 50,000 inhabitants | 32 (32.3) | 4 (4.0) | 63 (63.7) | 53 (53.5) | 4 (4.0) | 42 (42.5) | |||
City of 50,000–250,000 inhabitants | 45 (33.8) | 3 (2.3) | 85 (63.9) | 103 (77.4) | 7 (5.3) | 23 (17.3) | |||
City with more than 250,000 inhabitants | 84 (33.3) | 4 (1.6) | 164 (65.1) | 198 (78.6) | 7 (2.8) | 47 (18.6) | |||
Education | Higher | 170 (34.9) | 11 (2.3) | 306 (62.8) | 0.143 | 362 (74.3) | 11 (2.3) | 114 (23.4) | <0.001 |
Secondary | 20 (25.9) | 4 (5.2) | 53 (68.9) | 46 (59.7) | 11 (14.3) | 20 (26.0) | |||
Other | --- | --- | --- | --- | --- | --- | |||
Relationship status | Single | 39 (35.5) | 0 (0.0) | 71 (64.5) | 0.003 | 88 (80.0) | 0 (0.0) | 22 (20.0) | <0.001 |
Partnership | 22 (21.4) | 8 (7.8) | 73 (70.8) | 58 (56.3) | 11 (10.7) | 34 (33.0) | |||
Married | 129 (36.8) | 7 (2.0) | 215 (61.2) | 262 (74.6) | 11 (3.1) | 78 (22.3) | |||
Healthcare professional | Yes | 75 (37.7) | 3 (1.5) | 121 (60.8) | 0.178 | 159 (79.9) | 4 (2.0) | 36 (18.1) | 0.007 |
No | 115 (31.5) | 12 (3.3) | 238 (65.2) | 249 (68.2) | 18 (4.9) | 98 (26.9) | |||
Chronic conditions | Yes | 88 (34.7) | 0 (0.0) | 166 (65.3) | 0.001 | 204 (80.3) | 7 (2.8) | 43 (16.9) | <0.001 |
No | 102 (32.9) | 15 (4.8) | 193 (62.3) | 204 (65.8) | 15 (4.8) | 91 (23.4) | |||
Vaccination against COVID-19 | Booster dose | 166 (42.6) | 0 (0.0) | 224 (57.4) | <0.001 | 339 (86.9) | 4 (1.0) | 47 (12.1) | <0.001 |
Basic vaccination scheme | 20 (21.9) | 11 (11.6) | 64 (67.4) | 62 (65.3) | 11 (11.6) | 22 (23.1) | |||
Unvaccinated | 4 (5.1) | 4 (5.1) | 71 (89.8) | 7 (8.9) | 7 (8.9) | 65 (82.2) | |||
Vaccination history | Mandatory and recommended | 128 (43.4) | 4 (1.4) | 163 (55.2) | <0.001 | 261 (88.5) | 4 (1.4) | 30 (10.1) | <0.001 |
Only mandatory | 54 (23.4) | 7 (3.0) | 170 (73.6) | 131 (56.7) | 15 (6.5) | 85 (36.8) | |||
No | 8 (4.1) | 4 (10.5) | 26 (68.4) | 16 (42.1) | 3 (7.9) | 19 (50.0) | |||
Willingness to take the booster dose | Yes, as soon as possible | 132 (44.2) | 0 (0.0) | 167 (55.8) | <0.001 | 289 (96.7) | 0 (0.0) | 10 (3.3) | <0.001 |
Yes, within a year | 36 (52.2) | 0 (0.0) | 33 (47.8) | 63 (91.3) | 0 (0.0) | 6 (8.7) | |||
Yes, but in a year or more | 0 (0.0) | 0 (0.0) | 8 (100) | 0 (0.0) | 4 (50.0) | 4 (50.0) | |||
I cannot decide | 15 (32.6) | 0 (0.0) | 31 (67.4) | 35 (76.1) | 3 (6.5) | 8 (17.4) | |||
No, but maybe in the future | 7 (16.3) | 7 (16.3) | 29 (67.4) | 21 (48.8) | 4 (9.3) | 18 (41.9) | |||
No, never | 0 (0.0) | 8 (8.1) | 91 (91.9) | 0 (0.0) | 11 (11.1) | 88 (88.9) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Babicki, M. Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles? Vaccines 2022, 10, 1658. https://doi.org/10.3390/vaccines10101658
Babicki M. Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles? Vaccines. 2022; 10(10):1658. https://doi.org/10.3390/vaccines10101658
Chicago/Turabian StyleBabicki, Mateusz. 2022. "Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?" Vaccines 10, no. 10: 1658. https://doi.org/10.3390/vaccines10101658
APA StyleBabicki, M. (2022). Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles? Vaccines, 10(10), 1658. https://doi.org/10.3390/vaccines10101658